(daw noe ROO bi sin lye po SO mal)
- DAUNOrubicin Citrate
- DAUNOrubicin Citrate (Liposomal)
- DAUNOrubicin Citrate Liposome
- Liposomal DAUNOrubicin
Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product
Injectable, Intravenous [preservative free]:
DaunoXome: 2 mg/mL (25 mL [DSC]) [pyrogen free]
Brand Names: U.S.
- DaunoXome [DSC]
- Antineoplastic Agent, Anthracycline
- Antineoplastic Agent, Topoisomerase II Inhibitor
Liposomal preparation of daunorubicin; liposomes have been shown to penetrate solid tumors more effectively, possibly because of their small size and longer circulation time. Once in tissues, daunorubicin is released (over time). Daunorubicin inhibits DNA and RNA synthesis by intercalation between DNA base pairs and by steric obstruction; and intercalates at points of local uncoiling of the double helix. Although the exact mechanism is unclear, it appears that direct binding to DNA (intercalation) and inhibition of DNA repair (topoisomerase II inhibition) result in blockade of DNA and RNA synthesis and fragmentation of DNA.
Vd: ~5 to 8 L
Daunorubicinol (major active metabolite) is detected at low levels in plasma
Primarily feces; some urine
Distribution: 4.4 hours
Use: Labeled Indications
Kaposi sarcoma: First-line treatment of advanced HIV-associated Kaposi sarcoma
Limitation of use: Daunorubicin (liposomal) is not recommended in HIV-related Kaposi sarcoma which is less than advanced.
Hypersensitivity to daunorubicin (liposomal) or any component of the formulation
Documentation of allergenic cross-reactivity for drugs in this class is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.
Note: DAUNOrubicin (liposomal) is different from the conventional DAUNOrubicin formulation; do NOT substitute (indications and doses are different).
Kaposi sarcoma: IV: 40 mg/m2 once every 2 weeks; continue until disease progression.
Refer to adult dosing.
Dosing: Renal Impairment
Serum creatinine >3 mg/dL: Administer 50% of normal dose.
Dosing: Hepatic Impairment
Bilirubin 1.2 to 3 mg/dL: Administer 75% of normal dose.
Bilirubin >3 mg/dL: Administer 50% of normal dose.
Dosing: Adjustment for Toxicity
ANC <750/mm3: Withhold treatment.
Infusion reactions (back pain, flushing, chest tightness): Temporarily interrupt infusion; may resume at a slower rate.
ASCO Guidelines for appropriate chemotherapy dosing in obese adults with cancer: Utilize patient’s actual body weight (full weight) for calculation of body surface area- or weight-based dosing, particularly when the intent of therapy is curative; manage regimen-related toxicities in the same manner as for nonobese patients; if a dose reduction is utilized due to toxicity, consider resumption of full weight-based dosing with subsequent cycles, especially if cause of toxicity (eg, hepatic or renal impairment) is resolved (Griggs 2012).
The only fluid that may be mixed with daunorubicin (liposomal) is D5W. Dilute with an equivalent volume of D5W to a 1:1 solution (to a concentration of 1 mg daunorubicin liposomal/mL). Must not be mixed with saline, bacteriostatic agents (such as benzyl alcohol), or any other solution. Do not mix with other medications.
Infuse over 1 hour; do not mix with other drugs. Do NOT administer with an in-line filter. Avoid extravasation.
See Trissel’s IV Compatibility Database
Store intact vials at 2°C to 8°C (36°F to 46°F); do not freeze. Protect from light. Diluted daunorubicin liposomal for infusion in D5W may be refrigerated at 2°C to 8°C (36°F to 46°F) for a maximum of 6 hours (if not used immediately).
Ado-Trastuzumab Emtansine: May enhance the cardiotoxic effect of Antineoplastic Agents (Anthracycline, Systemic). Management: When possible, patients treated with ado-trastuzumab emtansine should avoid anthracycline-based therapy for up to 7 months after stopping ado-trastuzumab emtansine. Monitor closely for cardiac dysfunction in patients receiving this combination. Consider therapy modification
BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). Avoid combination
BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). Avoid combination
Bevacizumab: May enhance the cardiotoxic effect of Antineoplastic Agents (Anthracycline, Systemic). Monitor therapy
Cardiac Glycosides: May diminish the cardiotoxic effect of Antineoplastic Agents (Anthracycline, Systemic). Antineoplastic Agents (Anthracycline, Systemic) may decrease the serum concentration of Cardiac Glycosides. The effects of liposomal formulations may be unique from those of the free drug, as liposomal formulation have unique drug disposition and toxicity profiles, and liposomes themselves may alter digoxin absorption/distribution. Monitor therapy
CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. Monitor therapy
Coccidioides immitis Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioides immitis Skin Test. Monitor therapy
Cyclophosphamide: May enhance the cardiotoxic effect of Antineoplastic Agents (Anthracycline, Systemic). Monitor therapy
Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone. Avoid combination
Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased. Monitor therapy
Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased Avoid combination
Echinacea: May diminish the therapeutic effect of Immunosuppressants. Consider therapy modification
Fingolimod: Immunosuppressants may enhance the immunosuppressive effect of Fingolimod. Management: Avoid the concomitant use of fingolimod and other immunosuppressants when possible. If combined, monitor patients closely for additive immunosuppressant effects (eg, infections). Consider therapy modification
Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased. Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants. Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly. Consider therapy modification
Lenograstim: Antineoplastic Agents may diminish the therapeutic effect of Lenograstim. Consider therapy modification
Lumacaftor: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. Lumacaftor may increase the serum concentration of P-glycoprotein/ABCB1 Substrates. Monitor therapy
Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. Avoid combination
Nivolumab: Immunosuppressants may diminish the therapeutic effect of Nivolumab. Consider therapy modification
Ocrelizumab: May enhance the immunosuppressive effect of Immunosuppressants. Monitor therapy
Palifermin: May enhance the adverse/toxic effect of Antineoplastic Agents. Specifically, the duration and severity of oral mucositis may be increased. Management: Do not administer palifermin within 24 hours before, during infusion of, or within 24 hours after administration of myelotoxic chemotherapy. Consider therapy modification
P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.). Monitor therapy
P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.). Monitor therapy
Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants. Avoid combination
Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents. Monitor therapy
Ranolazine: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. Monitor therapy
Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants. Consider therapy modification
Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T. Monitor therapy
Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants. Avoid combination
Taxane Derivatives: May enhance the adverse/toxic effect of Antineoplastic Agents (Anthracycline, Systemic). Taxane Derivatives may increase the serum concentration of Antineoplastic Agents (Anthracycline, Systemic). Taxane Derivatives may also increase the formation of toxic anthracycline metabolites in heart tissue. Consider therapy modification
Tertomotide: Immunosuppressants may diminish the therapeutic effect of Tertomotide. Monitor therapy
Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib. Management: Concurrent use with antirheumatic doses of methotrexate or nonbiologic disease modifying antirheumatic drugs (DMARDs) is permitted, and this warning seems particularly focused on more potent immunosuppressants. Avoid combination
Trastuzumab: May enhance the cardiotoxic effect of Antineoplastic Agents (Anthracycline, Systemic). Management: When possible, patients treated with trastuzumab should avoid anthracycline-based therapy for up to 7 months after stopping trastuzumab. Monitor closely for cardiac dysfunction in patients receiving anthracyclines with trastuzumab. Consider therapy modification
Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated). Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation. Consider therapy modification
Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Immunosuppressants may diminish the therapeutic effect of Vaccines (Live). Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants. Avoid combination
Frequency not always defined.
Cardiovascular: Edema (11%), chest pain (10%), angina pectoris (≤5%), atrial fibrillation (≤5%), cardiac arrest (≤5%), cardiac tamponade (≤5%), hypertension (≤5%), myocardial infarction (≤5%), palpitations (≤5%), pericardial effusion (≤5%), pulmonary hypertension (≤5%), sinus tachycardia (≤5%), supraventricular tachycardia (≤5%), syncope (≤5%), tachycardia (≤5%), ventricular premature contractions (≤5%), decreased left ventricular ejection fraction (3%; reduction of 20% to 25%), cardiomyopathy (cumulative, dose-related; total dose above 300 mg/m2)
Central nervous system: Fatigue (49%), headache (25%), rigors (19%), neuropathy (13%), depression (10%), malaise (10%), dizziness (8%), insomnia (6%), abnormality in thinking (≤5%), amnesia (≤5%), anxiety (≤5%), ataxia (≤5%), confusion (≤5%), drowsiness (≤5%), emotional lability (≤5%), hallucination (≤5%), hypertonia (≤5%), meningitis (≤5%), seizure (≤5%)
Dermatologic: Diaphoresis (14%), alopecia (8%), pruritus (7%), folliculitis (≤5%), seborrhea (≤5%), xeroderma (≤5%)
Endocrine & metabolic: Dehydration (≤5%), hot flash (≤5%), increased thirst (≤5%)
Gastrointestinal: Nausea (54%), diarrhea (38%), abdominal pain (23%), anorexia (23%), vomiting (23%), stomatitis (10%), constipation (7%), tenesmus (5%), dental caries (≤5%), dysgeusia (≤5%), dysphagia (≤5%), gastritis (≤5%), gastrointestinal hemorrhage (≤5%), gingival hemorrhage (≤5%), hemorrhoids (≤5%), hiccups (≤5%), increased appetite (≤5%), melena (≤5%), xerostomia (≤5%)
Genitourinary: Dysuria (≤5%), nocturia (≤5%)
Hematologic & oncologic: Neutropenia (<1,000 cells/mm3: 36%; grade 4: 15%), lymphadenopathy (≤5%), splenomegaly (≤5%), bone marrow depression (especially granulocytes; platelets and erythrocytes less effected), severe granulocytopenia (may be associated with fever and result in infection)
Hepatic: Hepatomegaly (≤5%)
Hypersensitivity: Hypersensitivity reaction (24%)
Infection: Opportunistic infection (40%; median time to first infection/illness: 214 days)
Local: inflammation at injection site (≤5%)
Neuromuscular & skeletal: Back pain (16%), arthralgia (7%), myalgia (7%), abnormal gait (≤5%), hyperkinesia (≤5%), tremor (≤5%)
Ophthalmic: Visual disturbance (5%), conjunctivitis (≤5%), eye pain (≤5%)
Otic: Deafness (≤5%), otalgia (≤5%), tinnitus (≤5%)
Renal: Polyuria (≤5%)
Respiratory: Cough (28%), dyspnea (26%), rhinitis (12%), sinusitis (8%), flu-like symptoms (5%), hemoptysis (≤5%), increased bronchial secretions (≤5%), pulmonary infiltrates (≤5%)
Miscellaneous: Fever (47%), infusion-related reaction (14%; includes back pain, flushing, chest tightness)
Concerns related to adverse effects:
• Bone marrow suppression: [US Boxed Warning]: May cause bone marrow suppression, particularly neutropenia (may be severe). Monitor blood counts. Monitor closely for infections (including opportunistic infections).
• Extravasation: Avoid extravasation. Although not reported with daunorubicin (liposomal), daunorubicin (conventional) is associated with local tissue necrosis if extravasated.
• Infusion reactions: [US Boxed Warning]: The lipid component is associated with infusion-related reactions (back pain, flushing, chest tightness) usually within the first 5 minutes of infusion, and subsides with interruption of the infusion, and generally does not recur if the infusion is resumed at a lower rate. Monitor for infusion reactions; interrupt infusion if reaction occurs, and resume at reduced infusion rate.
• Myocardial toxicity: [US Boxed Warning]: Due to the potential for cardiac toxicity and heart failure, monitor cardiac function regularly, especially in patients with previous therapy with anthracyclines, thoracic radiation, or who have preexisting cardiac disease. Cardiomyopathy is usually associated with a decrease left in ventricular ejection fraction (LVEF). Although the risk increases with cumulative dose, irreversible cardiotoxicity may occur with anthracycline treatment at any dose level. Patients who have received prior anthracycline therapy (DOXOrubicin >300 mg/m2 or equivalent), with preexisting heart disease, hypertension, concurrent administration of other antineoplastic agents, prior or concurrent chest irradiation, and advanced age are at increased risk. Evaluate LVEF prior to treatment and periodically during treatment (at cumulative doses of daunorubicin liposomal 320 mg/m2 and every 160 mg/m2 thereafter or every 160 mg/m2 in patients at higher risk).
• Hepatic impairment: [US Boxed Warning]: Reduce dosage in patients with hepatic impairment.
• Renal impairment: Use with caution in patients with renal impairment; may require dosage reduction.
Concurrent drug therapy issues:
• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.
• Experienced physician: [US Boxed Warning]: Should be administered under the supervision of an experienced cancer chemotherapy physician.
CBC with differential and platelets (prior to each dose), liver function tests, renal function tests; evaluate cardiac function (baseline left ventricular ejection fraction [LVEF] prior to treatment initiation; repeat LVEF at total cumulative doses of 320 mg/m2, and every 160 mg/m2 thereafter; patients with preexisting cardiac disease, history of prior chest irradiation, or history of prior anthracycline treatment should have baseline LVEF and every 160 mg/m2 thereafter); signs and symptoms of infection or disease progression; monitor closely for infusion reactions
Pregnancy Risk Factor
Adverse events were observed in animal reproduction studies. May cause fetal harm if administered during pregnancy. Women of childbearing potential should avoid becoming pregnant while receiving treatment.
• Discuss specific use of drug and side effects with patient as it relates to treatment. (HCAHPS: During this hospital stay, were you given any medicine that you had not taken before? Before giving you any new medicine, how often did hospital staff tell you what the medicine was for? How often did hospital staff describe possible side effects in a way you could understand?)
• Patient may experience flu-like symptoms, urine discoloration, abdominal pain, lack of appetite, hair loss, headache, cough, back pain, mouth irritation, lip irritation, or rhinorrhea. Have patient report immediately to prescriber signs of heart problems (cough or shortness of breath that is new or worse, swelling of the ankles or legs, abnormal heartbeat, weight gain of more than five pounds in 24 hours, dizziness, or passing out), signs of infection, angina, passing out, burning or numbness feeling, severe nausea, vomiting, excessive weight loss, severe diarrhea, bruising, bleeding, loss of strength and energy, vision changes, depression, or injection site pain or irritation (HCAHPS).
• Educate patient about signs of a significant reaction (eg, wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat). Note: This is not a comprehensive list of all side effects. Patient should consult prescriber for additional questions.
Intended Use and Disclaimer: Should not be printed and given to patients. This information is intended to serve as a concise initial reference for health care professionals to use when discussing medications with a patient. You must ultimately rely on your own discretion, experience, and judgment in diagnosing, treating, and advising patients.
More about daunorubicin liposomal
- Side Effects
- During Pregnancy
- Dosage Information
- Drug Interactions
- Support Group
- En Español
- 0 Reviews – Add your own review/rating
- Drug class: antibiotics/antineoplastics